S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
NASDAQ:GMAB

Genmab A/S (GMAB) Stock Forecast, Price & News

$39.57
+0.24 (+0.61%)
(As of 06/2/2023 ET)
Compare
Today's Range
$39.02
$39.57
50-Day Range
$37.12
$42.94
52-Week Range
$26.19
$47.50
Volume
258,086 shs
Average Volume
469,137 shs
Market Capitalization
$26.11 billion
P/E Ratio
35.65
Dividend Yield
N/A
Price Target
$39.15

Genmab A/S MarketRank™ Forecast

Analyst Rating
Hold
2.08 Rating Score
Upside/​Downside
1,498.7% Upside
$632.62 Price Target
Short Interest
Healthy
0.51% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.74mentions of Genmab A/S in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
30.30%
From $0.99 to $1.29 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.40 out of 5 stars

Medical Sector

181st out of 983 stocks

Pharmaceutical Preparations Industry

78th out of 486 stocks


GMAB stock logo

About Genmab A/S (NASDAQ:GMAB) Stock

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998 and is headquartered in Copenhagen, Denmark.

Receive GMAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter.

GMAB Stock News Headlines

SVB Securities Sticks to Its Hold Rating for Genmab (GMAB)
AI Creates New Cancer Drug - In Just 30 Days!
On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...
AI Creates New Cancer Drug - In Just 30 Days!
On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...
Genmab A/S (NASDAQ:GMAB) Shares Gap Up to $40.35
8 Best Biotech Stocks to Buy in 2023
Price Over Earnings Overview: Genmab
See More Headlines

GMAB Price History

GMAB Company Calendar

Last Earnings
11/10/2021
Today
6/02/2023
Next Earnings (Estimated)
8/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GMAB
Fax
N/A
Employees
1,660
Year Founded
1999

Price Target and Rating

Average Stock Price Forecast
$632.62
High Stock Price Forecast
$3,600.00
Low Stock Price Forecast
$31.00
Forecasted Upside/Downside
-1.1%
Consensus Rating
Hold
Rating Score (0-4)
2.08
Research Coverage
12 Analysts

Profitability

Net Income
$781.91 million
Pretax Margin
44.26%

Debt

Sales & Book Value

Annual Sales
$2.07 billion
Cash Flow
$1.27 per share
Book Value
$5.94 per share

Miscellaneous

Free Float
649,697,000
Market Cap
$26.11 billion
Optionable
Not Optionable
Beta
0.96

Social Links


Key Executives

  • Jan G. J. van de Winkel
    President & Chief Executive Officer
  • Anthony Mancini
    Chief Operating Officer & Executive Vice President
  • Anthony Pagano
    Chief Financial Officer & Executive Vice President
  • Tahamtan Ahmadi
    Chief Medical Officer & Executive Vice President
  • Martine J. van Vugt
    Chief Strategy Officer & Executive Vice President













GMAB Stock - Frequently Asked Questions

Should I buy or sell Genmab A/S stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genmab A/S in the last year. There are currently 2 sell ratings, 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" GMAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GMAB, but not buy additional shares or sell existing shares.
View GMAB analyst ratings
or view top-rated stocks.

What is Genmab A/S's stock price forecast for 2023?

12 Wall Street analysts have issued 12-month price targets for Genmab A/S's shares. Their GMAB share price forecasts range from $31.00 to $3,600.00. On average, they expect the company's stock price to reach $632.62 in the next twelve months. This suggests a possible upside of 1,498.7% from the stock's current price.
View analysts price targets for GMAB
or view top-rated stocks among Wall Street analysts.

How have GMAB shares performed in 2023?

Genmab A/S's stock was trading at $42.38 at the start of the year. Since then, GMAB shares have decreased by 6.6% and is now trading at $39.57.
View the best growth stocks for 2023 here
.

When is Genmab A/S's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our GMAB earnings forecast
.

How were Genmab A/S's earnings last quarter?

Genmab A/S (NASDAQ:GMAB) posted its earnings results on Wednesday, November, 10th. The company reported $0.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.10. The business had revenue of $366.25 million for the quarter, compared to analysts' expectations of $341.46 million. Genmab A/S had a trailing twelve-month return on equity of 19.67% and a net margin of 34.34%. During the same period in the previous year, the firm posted $0.13 EPS.

What guidance has Genmab A/S issued on next quarter's earnings?

Genmab A/S updated its FY 2023 earnings guidance on Friday, May, 26th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.94 billion-$2.13 billion, compared to the consensus revenue estimate of $2.31 billion.

What other stocks do shareholders of Genmab A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genmab A/S investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), CVS Health (CVS), Home Depot (HD), Intel (INTC), Pfizer (PFE), PayPal (PYPL), Verizon Communications (VZ) and Cisco Systems (CSCO).

When did Genmab A/S IPO?

(GMAB) raised $503 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 27,800,000 shares at a price of $18.11 per share. BofA Merrill Lynch, Morgan Stanley and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and RBC Capital Markets were co-managers.

What is Genmab A/S's stock symbol?

Genmab A/S trades on the NASDAQ under the ticker symbol "GMAB."

Who are Genmab A/S's major shareholders?

Genmab A/S's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (0.80%), Macquarie Group Ltd. (0.53%), Wellington Management Group LLP (0.37%), 1832 Asset Management L.P. (0.34%), First Trust Advisors LP (0.19%) and Envestnet Asset Management Inc. (0.17%).

How do I buy shares of Genmab A/S?

Shares of GMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Genmab A/S's stock price today?

One share of GMAB stock can currently be purchased for approximately $39.57.

How much money does Genmab A/S make?

Genmab A/S (NASDAQ:GMAB) has a market capitalization of $26.11 billion and generates $2.07 billion in revenue each year. The company earns $781.91 million in net income (profit) each year or $1.11 on an earnings per share basis.

How many employees does Genmab A/S have?

The company employs 1,660 workers across the globe.

How can I contact Genmab A/S?

Genmab A/S's mailing address is Kalvebod Brygge 43, Copenhagen G7, 1560. The official website for the company is www.genmab.com. The company can be reached via phone at (457) 020-2728 or via email at acn@genmab.com.

This page (NASDAQ:GMAB) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -